Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Esper Biosciences Inc
Profile last edited on: 1/8/24      CAGE: 7J0K7      UEI: ZS9LQHKMMG16

Business Identifier: Nanopore-integrated nanotube sensors for better, smaller, faster, DNA sequencing research.
Year Founded
2016
First Award
2016
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

610 North Cayuga Street
Ithaca, NY 14850
   (607) 220-4690
   N/A
   N/A
Location: Single
Congr. District: 23
County: Tompkins

Public Profile

Despite having sucessfully taken four NIH awards, and with ties to Cornell, Esper Biosciences is a very low profile firm with minimal online presence. The firm is descibed as aiming to develop a low-cost, high-speed DNA sequencer, for use in point-of-care medical diagnostics and scientific research.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,059,750
Phase II Dollars
$0
Total Awarded
$1,059,750

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $299,889
Project Title: Hepatitis C Diagnostics Using Nanopore Field-Effect Sensors
2020 1 NIH $329,887
Project Title: DNA Labeling for Improved Synthetic Long Reads
2017 1 NIH $279,974
Project Title: Epigenetic Fingerprinting of Label-Free Dna Using a Solid-State Nanopore
2016 1 NIH $150,000
Project Title: Nanopore-Integrated Carbon Nanotube Sensors for Dna Sequencing

Key People / Management

  Jonathan Alden -- Founder and CEO

Company News

There are no news available.